Objective:The aim of the present study was to isolate the anti-MRSA(Methicillin Resistant Staphylococcus aureus)molecule from the Mangrove symbiont Streptomyces and its biomedical studies in Zebrafish embryos.Methods:...Objective:The aim of the present study was to isolate the anti-MRSA(Methicillin Resistant Staphylococcus aureus)molecule from the Mangrove symbiont Streptomyces and its biomedical studies in Zebrafish embryos.Methods:MRSA was isolated from the pus samples of Colachal hospitals and confirmed by amplification of mecA gene.Anti-MRSA molecule producing strain was identified by!6s rRNA gene sequencing.Anti-MRSA compound production was optimized by Solid State Fermentation(SSF)and the purification of the active molecule was carried out by TLC and RP-HPLC.The inhibitory concentration and LC_(50)were calculated using Statistical software SPSS.The Biomedical studies including the cardiac assay and organ toxicity assessment were carried out in Zebraiish.Results:The bioactive anti-MRSA small molecule A,was purified by TLC with Rf value of 0.37 with 1.389 retention time at RP-HPLC.The Inhibitory Concentration of the purified molecule A_2 was 30μg/mL but,the inhibitory concentration of the MRSA in the infected embryo was 32-34μg/mL for TLC purified molecule A,with LC_(50)mean value was61.504μg/mL.Zebrafish toxicity was assessed in 48-60μg/mL by observing the physiological deformities and the heart beat rates(HBR)of embryos for anti MRSA molecule showed the mean of 41.33-41.67 HBR/15 seconds for 40μg/mL and control was 42.33-42.67 for 15 seconds which significantly showed that the anti-MRSA molecule A_2 did not affected the HBR.Conclusions:Anti-MRSA molecule from Streptomyces sp PVRK-I was isolated and biomedical studies in Zebrafish model assessed that the molecule was non toxic at the minimal inhibitory concentration of MRSA.展开更多
Methicillin-resistant Staphylococcus aureus(MRSA)has remained a major threat to healthcare;in both hospital and community settings over the past five decades.With the current use of antibiotics for a variety of infect...Methicillin-resistant Staphylococcus aureus(MRSA)has remained a major threat to healthcare;in both hospital and community settings over the past five decades.With the current use of antibiotics for a variety of infections,including MRSA,emerging resistance is a major concern.Currently available treatments have restrictions limiting their use.These issues include,but are not limited to,side effects,cross-resistance,lack of understanding of pharmacokinetics and clinical pharmacodynamics,gradual increment in minimal inhibitory concentration over the period(MIC creep)and ineffectiveness in dealing with bacterial biofilms.Despite availability of various therapeutic options for MRSA,the clinical cure rates remain low with high morbidity and mortality.Given these challenges with existing treatments,there is a need for development of novel agents for MRSA.Along with prompt infection control strategies and strict implementation of antibiotic stewardship,cautious use of newer anti-MRSA agents will be of utmost importance.This article reviews the treatments and limitations of MRSA management and highlights the future path.展开更多
Objective:To determine the clinical implication of and intestinal carriage with methicillin resistant Staphylococcus aureus(MRSA) and extended spectrumβ-lactamase(ESBL)-producing Enterobacteriacae.Methods: A total of...Objective:To determine the clinical implication of and intestinal carriage with methicillin resistant Staphylococcus aureus(MRSA) and extended spectrumβ-lactamase(ESBL)-producing Enterobacteriacae.Methods: A total of 180 stool specimens were screened for MRSA and ESBL-producing enterobacteria.Identification of ESBL- producing Enterobacteriacae was done by MicroScan Walk Away 96 system(Dade Behring Inc.,West Sacramento,CA 95691,USA ) and confirmation by double-disc synergy test.MRSA was identified by disc diffusion using 30μg cefoxitin disc and the MicroScan.Results:The rate of fecal MRSA carriage was 7.8% (14/180),35.7%(5 /14) were recovered from surgical wards.Three patients(21,4%) had MRSA recovered from other body sites,and 2(14.2%) had in addition ESBL -producing Escherichia coli(E.coli) and Klebsiella pneumoniae(K.pneumoniae) respectively.Four(28.5%) patients with MRSA fical carriage died. MRSA fecal carriage was recovered from both inpatients and outpatients.Four(2.2%) cases carried ESBL-producing Enterobacteriacae in feces.Three(75%) were from intensive care unit(ICU).One patient had both ESBL-producing E.coli and K.pneumoniae from stool as well as E.coli from tracheal aspirate.Two ICU patients with fecal ESBL died.Conclusion:Fecal screening for MRSA and ESBL of all patients at high risk admitted to different hospital wards and ICUs and implementing infection control measures were recommended.展开更多
基金Supported by Xpression Biotek Ltd.and International Centre for Nanobiotechnology(ICN).Manonmaniam Sundaranar University
文摘Objective:The aim of the present study was to isolate the anti-MRSA(Methicillin Resistant Staphylococcus aureus)molecule from the Mangrove symbiont Streptomyces and its biomedical studies in Zebrafish embryos.Methods:MRSA was isolated from the pus samples of Colachal hospitals and confirmed by amplification of mecA gene.Anti-MRSA molecule producing strain was identified by!6s rRNA gene sequencing.Anti-MRSA compound production was optimized by Solid State Fermentation(SSF)and the purification of the active molecule was carried out by TLC and RP-HPLC.The inhibitory concentration and LC_(50)were calculated using Statistical software SPSS.The Biomedical studies including the cardiac assay and organ toxicity assessment were carried out in Zebraiish.Results:The bioactive anti-MRSA small molecule A,was purified by TLC with Rf value of 0.37 with 1.389 retention time at RP-HPLC.The Inhibitory Concentration of the purified molecule A_2 was 30μg/mL but,the inhibitory concentration of the MRSA in the infected embryo was 32-34μg/mL for TLC purified molecule A,with LC_(50)mean value was61.504μg/mL.Zebrafish toxicity was assessed in 48-60μg/mL by observing the physiological deformities and the heart beat rates(HBR)of embryos for anti MRSA molecule showed the mean of 41.33-41.67 HBR/15 seconds for 40μg/mL and control was 42.33-42.67 for 15 seconds which significantly showed that the anti-MRSA molecule A_2 did not affected the HBR.Conclusions:Anti-MRSA molecule from Streptomyces sp PVRK-I was isolated and biomedical studies in Zebrafish model assessed that the molecule was non toxic at the minimal inhibitory concentration of MRSA.
文摘Methicillin-resistant Staphylococcus aureus(MRSA)has remained a major threat to healthcare;in both hospital and community settings over the past five decades.With the current use of antibiotics for a variety of infections,including MRSA,emerging resistance is a major concern.Currently available treatments have restrictions limiting their use.These issues include,but are not limited to,side effects,cross-resistance,lack of understanding of pharmacokinetics and clinical pharmacodynamics,gradual increment in minimal inhibitory concentration over the period(MIC creep)and ineffectiveness in dealing with bacterial biofilms.Despite availability of various therapeutic options for MRSA,the clinical cure rates remain low with high morbidity and mortality.Given these challenges with existing treatments,there is a need for development of novel agents for MRSA.Along with prompt infection control strategies and strict implementation of antibiotic stewardship,cautious use of newer anti-MRSA agents will be of utmost importance.This article reviews the treatments and limitations of MRSA management and highlights the future path.
文摘Objective:To determine the clinical implication of and intestinal carriage with methicillin resistant Staphylococcus aureus(MRSA) and extended spectrumβ-lactamase(ESBL)-producing Enterobacteriacae.Methods: A total of 180 stool specimens were screened for MRSA and ESBL-producing enterobacteria.Identification of ESBL- producing Enterobacteriacae was done by MicroScan Walk Away 96 system(Dade Behring Inc.,West Sacramento,CA 95691,USA ) and confirmation by double-disc synergy test.MRSA was identified by disc diffusion using 30μg cefoxitin disc and the MicroScan.Results:The rate of fecal MRSA carriage was 7.8% (14/180),35.7%(5 /14) were recovered from surgical wards.Three patients(21,4%) had MRSA recovered from other body sites,and 2(14.2%) had in addition ESBL -producing Escherichia coli(E.coli) and Klebsiella pneumoniae(K.pneumoniae) respectively.Four(28.5%) patients with MRSA fical carriage died. MRSA fecal carriage was recovered from both inpatients and outpatients.Four(2.2%) cases carried ESBL-producing Enterobacteriacae in feces.Three(75%) were from intensive care unit(ICU).One patient had both ESBL-producing E.coli and K.pneumoniae from stool as well as E.coli from tracheal aspirate.Two ICU patients with fecal ESBL died.Conclusion:Fecal screening for MRSA and ESBL of all patients at high risk admitted to different hospital wards and ICUs and implementing infection control measures were recommended.
